&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-11, 22:10

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-12-06, 20:05

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2025-06-16, 19:30

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2024-07-09, 07:00

Io Therapeutics, Inc., announces presentation of data on induction of tumor growth inhibiting anti-cancer immune responses in multiple types of cancers by a IRX5010, a novel retinoic acid nuclear receptor agonist compound
Dora Legere

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-02-07, 04:32

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2023-02-02, 20:05

Surface Oncology to Participate in the 2023 Guggenheim

CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...

Popular Posts